Statistics from Altmetric.com
We thank the authors for their interest1 in our article ‘Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden’2, and for their effort in identifying genetic factors involved in the pathogenesis of both rheumatoid arthritis (RA) and venous thromboembolism (VTE).
As the authors suggest, identification of additional genetic loci associated with both diseases would be another important step in understanding the reasons behind the increased VTE risk in RA and might also help in identifying patients at particularly increased risk of VTE.
Handling editor Josef S Smolen
Contributors VM and JA contributed to the drafting of the response.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests Karolinska Institutet, with JA as principal investigator, has or has had research agreements with Abbvie, Astra-Zeneca, BMS, Eli Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB, mainly in the context of safety monitoring of biologics via ARTIS/Swedish Biologics Register.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.